Last reviewed · How we verify
NCT04304105
Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study
trial in Critical Limb Ischemia in 192 participants. Completed in 12 September 2022.
12 September 2022
Quick facts
| Lead sponsor | LimFlow, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 192 |
| Start date | 24 February 2020 |
| Primary completion | 12 September 2022 |
| Estimated completion | 12 September 2022 |
| Sites | 25 locations across Puerto Rico, United States |
Conditions studied
- Critical Limb Ischemia — all drugs for Critical Limb Ischemia →
- Peripheral Artery Disease — all drugs for Peripheral Artery Disease →
Sponsor
LimFlow, Inc.
Who can join
18 and older, any sex, with Critical Limb Ischemia or Peripheral Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this observational registry is to track the clinical progression of chronic limb-threatening ischemia (CLTI) and incidence of death, amputation, and revascularization attempts over a one-year period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04304105
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Critical Limb Ischemia
Currently open trials in the same condition.
- NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
- NCT06434194 — Serrantor OCT Study · NA · recruiting
- NCT06482892 — TP03HN106 in Patients With Critical Limb Ischemia · Phase 2 · recruiting
- NCT06296576 — Acceleration Time Assessment for Prediction of Critical Limb Ischemia · recruiting
- NCT06075940 — Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Diseas · NA · recruiting
Other LimFlow, Inc. trials
Trials by the same sponsor.
- NCT05313165 — PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia · NA · recruiting
- NCT03970538 — PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia · NA · unknown
- NCT03124875 — PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04304105 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LimFlow, Inc.
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04304105.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing